Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

Video

Dr Hope Rugo addresses some of the main differences between the 3 CDK4/6 inhibitors that are FDA-approved in HR-positive metastatic breast cancer.
Dr Hope Rugo cites that CDK4/6 inhibitors play a critical role in estrogen signaling and can be very effective in treating metastatic breast cancer when used in combination with hormone therapy.
The WCGIC chairperson, professor Eric Van Cutsem, MD, PhD, heads the Division of Digestive Oncology at University Hospitals Leuven and KU Leuven, Leuven, Belgium. He describes the difference between left- and right-sided colon cancers in terms of prognosis and response to therapy.
Dr. Valérie Vilgrain discusses SIRT Y-90 and the results of the SARAH trial.
Atheer Kaddis, SVP Sales/Business Development of Diplomat Specialty Pharmacy, describes in his opinion how specialty pharmacy can assist patients with polycythemia vera
Listen as Atheer Kaddis discusses the additional services that pharmacies can prescribe to patients with polycythemia vera and their families.
Atheer Kaddis presents his own personal advice on what pharmacists should do to navigate through the healthcare system.
Hear Atheer Kaddis describe how the role of the pharmacist is changing in hematology and oncology.
Atheer Kaddis presents the role of the pharmacist with regards to polycythemia vera and describes why it is unique.
Page 4 of 4
Results 31 - 39 of 39